Articles

Although there are several hereditary risk factors related to kidney cancer, there also are lifestyle choices that can increase a person’s risk of the disease. Read More ›

The US Food and Drug Administration (FDA) approved ado-trastuzumab emtansine (Kadcyla for injection; Genentech) for single-agent use for treating patients with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination. Approval for ado-trastuzumab emtansine was granted on February 22, 2013. Read More ›

With this issue of The Oncology Nurse-APN/PA (TON), we continue our coverage of the news from the 54th Annual Meeting of the American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Read More ›

The clinical response to regorafenib does not depend on tumor mutations. Among patients with metastatic colorectal cancer who participated in the phase 3 CORRECT (Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy) study, an analysis of tumor specimens for KRAS and PIK3CA mutations did not predict clinical benefit in the patients assigned to regorafenib compared with placebo, said Michael Jeffers, PhD. Read More ›

Studies have suggested that musculoskeletal toxicity associated with aromatase inhibitor therapy can lead to noncompliance in up to one-third of women with breast cancer. Read More ›

A wealth of abstracts were presented at the 54th Annual Meeting of the American Society of Hematology (ASH), held in Atlanta, Georgia, on December 8-11, 2012. More than 18,000 hematologists and other healthcare professionals from around the world gathered to discuss the latest clinical developments in research, therapies, and practice strategies. Attendees had the opportunity to review thousands of selected scientific abstracts. Following are some of the highlights from the ASH annual meeting. Read More ›

The Evolving Role of the Physician Assistant in Oncology Read More ›

The national survey of health professionals showed that drug shortages interrupted cancer research and increased cancer treatment expenses and risks. Read More ›

In a recent study, baldness in African-American men raised the risk of prostate cancer. Read More ›

Recent study findings show that women with breast cancer who discontinue their prescribed tamoxifen or aromatase inhibitors too early following initial treatment increase their chance of cancer recurrence and risk of dying. Read More ›